{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:12:33Z","timestamp":1783977153895,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Fundaci\u00f3 Instituci\u00f3 dels Centres de Recerca de Catalunya"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy, and Skin changes (POEMS) syndrome is a rare plasma cell disorder with diverse multisystem manifestations. Autologous stem cell transplantation (ASCT) is the preferred front-line therapy when feasible, but relapsed\/refractory (RR) cases after ASCT failure lack effective salvage options. B-cell maturation antigen (BCMA)-directed CAR-T cell therapy has revolutionised multiple myeloma (MM) treatment. Given the shared BCMA expression on clonal plasma cells between MM and POEMS, CAR-T cell therapy is also a biologically compelling strategy for POEMS syndrome [1]. However, there are only two previous case reports of CAR-T cell therapy in POEMS [3,4], none involving patients with prior ASCT failure. We report a 54-year-old male with RR-POEMS progressing after two previous ASCT failures who received an academic point-of-care BCMA-directed CAR-T cell therapy (ARI0002h) via fractionated infusion. No cytokine release syndrome (CRS) or neurotoxicity (ICANS) occurred. At 3 months, the patient achieved a measurable residual disease (MRD)-negative complete haematological response (CR\n                    <jats:sub>H<\/jats:sub>\n                    ) by Next Generation Flow (NGF) with a sensitivity of 10\u207b\u2076 and a radiological CR. Responses have been sustained for 10 months. Serum BCMA (sBCMA) levels declined dynamically in parallel with haematological response, suggesting potential utility as a novel monitoring biomarker in POEMS. This case supports BCMA-directed CAR-T therapy as a safe and effective salvage strategy in RR-POEMS following ASCT failure, even in an aggressive disease context.\n                  <\/jats:p>\n                  <jats:p>Clinical trial registration: Not aplicable.<\/jats:p>","DOI":"10.1007\/s00277-026-07063-4","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T22:32:56Z","timestamp":1778538776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Academic BCMA CAR-T (ARI0002h) achieves MRD-negative remission with sBCMA biomarker response in relapsed POEMS syndrome after double ASCT"],"prefix":"10.1007","volume":"105","author":[{"given":"V\u00edctor","family":"Torrecillas-Mayayo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aina","family":"Oliver-Caldes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Mart\u00ednez-Cibrian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nil","family":"Albiol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Gerardo","family":"Rodr\u00edguez-Lobato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Espa\u00f1ol-Rego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valent\u00edn","family":"Ortiz-Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rosi\u00f1ol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Tovar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Navarro-Velasquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Charry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Mun\u00e1rriz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Miguel","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Jimenez-Mira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Montoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Ayora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manel","family":"Juan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azucena","family":"Gonz\u00e1lez-Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Cibeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4930-9255","authenticated-orcid":false,"given":"Carlos","family":"Fern\u00e1ndez de Larrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"7063_CR1","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1002\/ajh.27081","volume":"98","author":"A Dispenzieri","year":"2023","unstructured":"Dispenzieri A (2023) POEMS syndrome: Update on diagnosis, risk-stratification, and management. Am J Hematol 98:1934\u20131950. https:\/\/doi.org\/10.1002\/ajh.27081","journal-title":"Am J Hematol"},{"key":"7063_CR2","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/bjh.18400","volume":"200","author":"J Khwaja","year":"2023","unstructured":"Khwaja J, D\u2019Sa S, Lunn MP, Sive J (2023) Evidence-based medical treatment of POEMS syndrome. Br J Haematol 200:128\u2013136. https:\/\/doi.org\/10.1111\/bjh.18400","journal-title":"Br J Haematol"},{"key":"7063_CR3","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13045-018-0672-7","volume":"11","author":"J Xu","year":"2018","unstructured":"Xu J, Wang Q, Xu H et al (2018) Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma. J Hematol Oncol 11:128. https:\/\/doi.org\/10.1186\/s13045-018-0672-7","journal-title":"J Hematol Oncol"},{"key":"7063_CR4","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.287702","author":"M Williams","year":"2025","unstructured":"Williams M, Atanackovic D, Mulatu R et al (2025) Cilta-cel CAR T cells as an effective and well tolerated treatment for POEMS: a case study. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2025.287702","journal-title":"Haematologica"},{"key":"7063_CR5","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S1470-2045(23)00222-X","volume":"24","author":"A Oliver-Cald\u00e9s","year":"2023","unstructured":"Oliver-Cald\u00e9s A, Gonz\u00e1lez-Calle V, Caba\u00f1as V et al (2023) Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study. Lancet Oncol 24:913\u2013924. https:\/\/doi.org\/10.1016\/S1470-2045(23)00222-X","journal-title":"Lancet Oncol"},{"key":"7063_CR6","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1158\/1078-0432.CCR-23-3759","volume":"30","author":"A Oliver-Caldes","year":"2024","unstructured":"Oliver-Caldes A, Espa\u00f1ol-Rego M, Zabaleta A et al (2024) Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma. Clin Cancer Res 30:2085\u20132096. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-3759","journal-title":"Clin Cancer Res"},{"key":"7063_CR7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","volume":"16","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Hansen DK, Bansal R et al (2023) The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma. J Hematol Oncol 16:88. https:\/\/doi.org\/10.1186\/s13045-023-01465-x","journal-title":"J Hematol Oncol"},{"key":"7063_CR8","doi-asserted-by":"publisher","first-page":"e009220","DOI":"10.1136\/jitc-2024-009220","volume":"12","author":"JH Frenking","year":"2024","unstructured":"Frenking JH, Zhou X, Wagner V et al (2024) EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed\/refractory multiple myeloma. J Immunother Cancer 12:e009220. https:\/\/doi.org\/10.1136\/jitc-2024-009220","journal-title":"J Immunother Cancer"},{"key":"7063_CR9","doi-asserted-by":"publisher","unstructured":"Moreno-Casta\u00f1o AB, Fern\u00e1ndez S, Brillembourg H et al (2026) m-EASIX (better than EASIX) predicts severe CAR T-cell toxicities, worse overall survival, and discriminates cytokine release syndrome from sepsis. Front Immunol 16. https:\/\/doi.org\/10.3389\/fimmu.2025.1664788","DOI":"10.3389\/fimmu.2025.1664788"},{"key":"7063_CR10","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1182\/blood.2023020578","volume":"142","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Subklewe M, Aljurf M et al (2023) Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations. Blood 142:865\u2013877. https:\/\/doi.org\/10.1182\/blood.2023020578","journal-title":"Blood"},{"key":"7063_CR11","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1182\/blood.2025028833","volume":"146","author":"K Rejeski","year":"2025","unstructured":"Rejeski K, Sanz J, Fei T et al (2025) T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy. Blood 146:834\u2013846. https:\/\/doi.org\/10.1182\/blood.2025028833","journal-title":"Blood"},{"key":"7063_CR12","doi-asserted-by":"publisher","unstructured":"Li A, Gao X, Zhao H et al (2024) Long-Term Outcomes of Autologous Stem Cell Transplantation in Patients with Newly Diagnosed POEMS Syndrome. Transplantation Cell Therapy 30. https:\/\/doi.org\/10.1016\/j.jtct.2023.11.001. :207.e1-207.e7","DOI":"10.1016\/j.jtct.2023.11.001"},{"key":"7063_CR13","doi-asserted-by":"publisher","first-page":"175628642312191","DOI":"10.1177\/17562864231219151","volume":"17","author":"F Fang","year":"2024","unstructured":"Fang F, Lan X-X, Hu R-H et al (2024) Efficacy of bortezomib, cyclophosphamide, and dexamethasone for newly diagnosed POEMS syndrome patients. Ther Adv Neurol Disord 17:17562864231219151. https:\/\/doi.org\/10.1177\/17562864231219151","journal-title":"Ther Adv Neurol Disord"},{"key":"7063_CR14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/cei\/uxae043","volume":"217","author":"P Guo","year":"2024","unstructured":"Guo P, Wang Y, He H et al (2024) Elevated serum levels of soluble B-cell maturation antigen as a prognostic biomarker for multiple myeloma. Clin Exp Immunol 217:221\u2013232. https:\/\/doi.org\/10.1093\/cei\/uxae043","journal-title":"Clin Exp Immunol"},{"key":"7063_CR15","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41408-021-00505-4","volume":"11","author":"A Visram","year":"2021","unstructured":"Visram A, Soof C, Rajkumar SV et al (2021) Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients. Blood Cancer J 11:120. https:\/\/doi.org\/10.1038\/s41408-021-00505-4","journal-title":"Blood Cancer J"},{"key":"7063_CR16","doi-asserted-by":"publisher","first-page":"100050","DOI":"10.1016\/j.modpat.2022.100050","volume":"36","author":"M Zhang","year":"2023","unstructured":"Zhang M, Gray F, Cushman I et al (2023) A Novel BCMA Immunohistochemistry Assay Reveals a Heterogenous and Dynamic BCMA Expression Profile in Multiple Myeloma. Mod Pathol 36:100050. https:\/\/doi.org\/10.1016\/j.modpat.2022.100050","journal-title":"Mod Pathol"},{"key":"7063_CR17","doi-asserted-by":"publisher","first-page":"7333","DOI":"10.1038\/ncomms8333","volume":"6","author":"SA Laurent","year":"2015","unstructured":"Laurent SA, Hoffmann FS, Kuhn P-H et al (2015) \u03b3-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat Commun 6:7333. https:\/\/doi.org\/10.1038\/ncomms8333","journal-title":"Nat Commun"},{"key":"7063_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1021\/acschembio.3c00592","volume":"19","author":"H-W Huang","year":"2024","unstructured":"Huang H-W, Chen C-C, Lin K-I et al (2024) Single Site N-Glycosylation of B Cell Maturation Antigen (BCMA) Inhibits \u03b3-Secretase-Mediated Shedding and Improves Surface Retention and Cell Survival. ACS Chem Biol 19:153\u2013161. https:\/\/doi.org\/10.1021\/acschembio.3c00592","journal-title":"ACS Chem Biol"},{"key":"7063_CR19","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","volume":"127","author":"Y-T Tai","year":"2016","unstructured":"Tai Y-T, Acharya C, An G et al (2016) APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood 127:3225\u20133236. https:\/\/doi.org\/10.1182\/blood-2016-01-691162","journal-title":"Blood"},{"key":"7063_CR20","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee H, Ahn S, Maity R et al (2023) Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med 29:2295\u20132306. https:\/\/doi.org\/10.1038\/s41591-023-02491-5","journal-title":"Nat Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07063-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07063-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07063-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:01:40Z","timestamp":1783976500000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07063-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":20,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["7063"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07063-4","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"30 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This manuscript reports a single, retrospective clinical case derived entirely from routine clinical care. No experimental intervention, prospective recruitment, randomization, or protocol-driven procedures were performed for the purpose of research. All diagnostic and therapeutic decisions were made according to standard clinical practice, independently of the preparation of this report.According to the institutional policy for clinical case reports, individual case descriptions that do not include identifiable patient information and do not involve research-related procedures are exempt from review by the Ethics Committee\/IRB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval statement"}},{"value":"Written informed consent has been obtained for publication of the case report and all accompanying images from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors confirm that written informed consent for compassionate use program of this treatment according to the institutional guidelines for clinical assistance.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent statement"}},{"value":"DFM received travel grants from Janssen and Sanofi, and honoraria from Janssen and BeOne. MTC received honoraria for lectures from Pfizer, Sanofi, Janssen, Amgen, and GlaxoSmithKline, and for completing a survey for AstraZeneca. CFL declares receiving grants through his institution from Bristol Myers Squibb, J&J, and Amgen; honoraria from Amgen, J&J, Bristol Myers Squibb, BeOne, GlaxoSmithKline, and Sanofi; reports support for attending meetings or travel from J&J, Bristol Myers Squibb, GlaxoSmithKline, and Amgen; and reports participation on advisory boards with J&J, Bristol Myers Squibb, Amgen, Pfizer, Roche, Oncopeptides, Menarini, AstraZeneca, BeOne and Sanofi. The remaining authors declare no conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not aplicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Permission to reproduce material from other sources"}}],"article-number":"317"}}